10.1158/2326-6066.Cir-23-0609 22 GautamN.EllesonK
Migraines, headaches, and relationship to b12 I feel like I spend half my life with a headache these days Theres definitely migraine with
16.26% for Argireline alone) Synergistic effects observed when combined with leuphasyl in dual-peptide formulations Non-inferior to pentapeptide-3 (Vialox) in smoothing expression lines Faster onset of visible effects compared to other topical neuromuscular peptides Molecular Interaction and Receptor Binding Studies Computational Docking and Dynamics Research Advanced in silico studies examined Syn-AKEs binding characteristics to multiple biological targets[3]: SIRT1 binding demonstrated highest affinity (-9.32 kcal/mol) among tested targets Stable binding maintained through 50 nanosecond molecular dynamics simulations Multiple interaction types (hydrogen bonds, salt bridges, pi-stacking) contribute to stability Binding pocket residues identified for potential structure-activity optimization Safety and Cytotoxicity Research Laboratory safety profiling using standard assays established preliminary safety parameters[3]: MTT cytotoxicity assays determined safe concentration ranges for topical formulations Ames genotoxicity testing showed no mutagenic activity at cosmetic use concentrations No sensitization or irritation reported in manufacturer testing (limited independent validation) Some anecdotal reports of skin reactions (redness, itching) in sensitive individuals Formulation and Penetration Research Studies examining topical delivery characteristics revealed[7]: Molecular weight below 500 Da threshold enables effective stratum corneum penetration Compatible with serum, cream, gel, and emulsion formulation bases Maintains stability in pH range 3.0-5.5 typical of cosmetic formulations Optimal use concentrations identified as 0.5-4% for topical applications Critical Research Context: While Syn-AKE has been studied extensively in in vitro systems and limited human topical application trials, comprehensive clinical trials examining long-term safety, optimal dosing, and mechanism validation remain limited
The three columns show the science-ready Eps Ind A image from the Spitzer archive (left), an RDI processed image with Eps Eri subtracted from Eps Ind A (centre), and the RDI processed image zoomed at the JWST epoch position of Eps Ind A (right)
